A new antiviral called Covid was found to be as effective as Paxlovid in controlling mild to moderate illness in people who were at high risk of severe illness in a phase 3 trial in China.
67% of patients reported side effects after using the treatment, whereas 77% of patients reported side effects after using paxlobid, which was published in the New England Journal of Medicine.
When combined with other medications, the new drugs also cause fewer reactions and adverse effects.
Junshi Biosciences and Vigonvita Life Sciences are the pharmaceutical companies that produce the medication VV116, which has an optimized formulation for tablet absorption by the body.
He received 380 of her five consecutive days of both drugs through this treatment. Patients taking Paxlovid and VV116 had median recovery times of 5 days and 4 days, respectively, from Covid.
98% of patients had recovered after four weeks, and none had developed severe COVID.
Co-author Ren Zhao, a professor at Shanghai Jiao Tong University School of Medicine, deemed the study successful.
However, medical professionals in the United States are eager to continue their research on the drug and conduct studies on larger and more diverse groups. According to NBC News, it will assist in determining the drug’s effectiveness against the new Omnicron variant.
